{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T19:54:52Z","timestamp":1723319692489},"reference-count":17,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.3892\/ol.2013.1603","type":"journal-article","created":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T13:09:53Z","timestamp":1380892193000},"page":"1779-1783","source":"Crossref","is-referenced-by-count":4,"title":["Bevacizumab treatment for advanced non-small cell lung cancer: A case report"],"prefix":"10.3892","volume":"6","author":[{"given":"YUN","family":"FAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHIYU","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEIMIN","family":"MAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,10,4]]},"reference":[{"key":"key20180108110236_b1-ol-06-06-1779","first-page":"122","article-title":"Treatment of advanced non small cell lung cancer","volume":"3","author":"Bareschino","year":"2011","journal-title":"J Thorac Dis"},{"key":"key20180108110236_b2-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","article-title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study","volume":"11","author":"Crin\u00f2","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20180108110236_b3-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180108110236_b4-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/JTO.0b013e3181da36f4","article-title":"Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel\/carboplatin for advanced non-small cell lung cancer","volume":"5","author":"Sandler","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180108110236_b5-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108110236_b6-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"key20180108110236_b7-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108110236_b8-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"key":"key20180108110236_b9-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-09-3100","article-title":"Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy","volume":"16","author":"Bagri","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180108110236_b10-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180108110236_b11-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1634\/theoncologist.2010-0287","article-title":"Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network","volume":"16","author":"Nadler","year":"2011","journal-title":"Oncologist"},{"key":"key20180108110236_b12-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180108110236_b13-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108110236_b14-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"key20180108110236_b15-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108110236_b16-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2009.11.018","article-title":"Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology","volume":"68","author":"Gridelli","year":"2010","journal-title":"Lung Cancer"},{"key":"key20180108110236_b17-ol-06-06-1779","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2013.1603\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T14:47:24Z","timestamp":1515422844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2013.1603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,4]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,10,4]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.3892\/ol.2013.1603"],"URL":"https:\/\/doi.org\/10.3892\/ol.2013.1603","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,4]]}}}